
Depot Vehicle Viscosity (Poise)
100
1000
10000
0.01
0.1
1
10
100
Shear rate (1/S)
o Formulation 5
Δ Formulation 7
L Formulation 6

FIG. 1


Depot vehicle Injection Force (N)
0
40
80
120
160
200
240
280
320
360
400
Formulation 5
Formulation 7
Formulation 6

FIG. 2


Depot Vehicle Injection Force (N)
0
40
80
120
160
200
240
280
320
360
400
16000
20000
24000
28000
32000
36000
MW of PLGA
BB as solvent
BA as solvent

FIG. 3


Depot Vehicle Injection Force (N)
0
40
80
120
160
200
240
280
320
360
400
440
40
45
50
55
60
Percent PLGA in the depot vehicle formulation (wt%)
100% BB
25% BA
100% BA

FIG. 5


Serum hGH Levels (ng/mL)
0.01
0.1
1
10
100
1000
0
4
8
12
16
20
24
28
Study days
Formulation 8
Formulation 9
Formulation 10

FIG. 6


Serum hGH Levels (ng/mL)
0.01
0.1
1
10
100
1000
0
4
8
12
16
20
24
28
Study days
Formulation 10
Formulation 11

FIG. 7


Bupivacaine plasma levels(ng/ml)
0.01
0.1
1
10
100
1000
0
1
2
3
4
5
6
7
8
9
10
Time (days)
Formulation 12
Formulation 13

FIG. 7

8/15


Bupivacaine plasma levels(ng/ml)
0.01
0.1
1
10
100
1000
0
2
4
6
8
10
Time (days)
Formulation 14
Formulation 13

FIG. 8


Bupivacaine plasma levels(ng/ml)
0.01
0.1
1
10
100
1000
0
2
4
6
8
10
Time (days)
Formulation 15
Formulation 16

FIG. 9


hGH monomer content (%)
50
55
60
65
70
75
80
85
90
95
100
Storage time (Months)
0
2
4
6
8
10
12
14
Formulation 8
Formulation 9
Formulation 10
Formulation 17

FIG. 10


Injection Force (N)
0
20
40
60
80
100
120
140
160
180
Particle Loading (wt%)
0
5
10
15
20
25
30
RG502/BB/BA, 40/45/15, 5 um particles
RG502/BB/BA, 40/45/15, 50 um particles
RG502/BB/BA, 40/45/15, 20 um particles
RG502/BA, 40/60, 5 um particles
RG502/BA, 40/60, 50 um particles
RG502/BA, 40/60, 20 um particles

FIG. 11


PDGF Monomer Content (%)
100
90
80
70
60
50
0
14
28
42
56
70
84
Time (Days)
Stability of PDGF in the depot Formulation at 5 °C
Formulation 36
Formulation 37
Formulation 38
Formulation 39

FIG. 12


PDGF Monomer Content (%)
50
60
70
80
90
100
0
14
28
42
56
70
84
Time (Days)
Formulation 36
Formulation 37
Formulation 38
Formulation 39
Stability of PDGF in the depot Formulation at 25°C

FIG. 13

14/15


PDGF Monomer Content (%)
50
60
70
80
90
100
0
7
14
21
28
Time (Days)
Formulation 36
Formulation 37
Formulation 38
Formulation 39
Stability of PDGF in the depot Formulation at 40°C

FIG. 14


Cumulative Release (%)
0
20
40
60
80
100
Time (day)
0
7
14
21
28
35
Formulation 36
Formulation 37
Formulation 38
Formulation 39

FIG. 15